6-APB is known to produce auditory hallucination, a auditory effect. Auditory hallucination is the perception of sounds that have no external source — hearing music, voices, environmental noises, or abstract sonic phenomena that exist entirely within the mind. These range from faint, ambiguous whispers at the edge of perception to fully formed, complex musical compositions or conversational speech that can feel completely real and externally sourced.
From a first-person perspective, auditory hallucinations manifest as sounds that feel genuinely external — as though they originate from somewhere in the physical environment — despite having no corresponding source. One may hear faint music playing from another room, indistinct conversational murmuring, environmental sounds like running water or wind, or entirely novel sonic phenomena such as buzzing, chiming, or crystalline tones. At higher intensities, full musical compositions may be perceived with remarkable complexity and fidelity, sometimes in genres or styles the listener has never heard before. Voices may speak coherent sentences, sometimes addressing the user directly, though insight is usually maintained that these are drug-induced.
At threshold levels, auditory hallucinations present as vague, ambiguous sounds — one might question whether a faint sound was real or imagined. At light to moderate intensities, the hallucinations become more distinct: identifiable snippets of music, recognizable whispered words, or phantom environmental sounds like doorbells or phone notifications. At strong doses, fully formed auditory experiences emerge — entire songs with lyrics, complex conversations, or rich environmental soundscapes that are indistinguishable from reality until one actively questions their origin. At overwhelming levels, the hallucinated audio can completely dominate the perceptual field, making it difficult to distinguish real from imagined sound.
Musical hallucinations involve hearing melodies, harmonies, or complete compositions, often novel and not drawn from memory.Verbal hallucinations consist of hearing words or sentences — these may be fragments, gibberish, or coherent speech.Environmental hallucinations replicate familiar ambient sounds (rain, traffic, appliances).Abstract sonic hallucinations produce sounds without clear real-world analogues — geometric buzzing, fractal tones, or sounds that seem to have visual or spatial properties. Auditory hallucinations can beopen-eye (perceived as external) orclosed-eye (perceived as internal, mind's-ear phenomena).
Auditory hallucinations arise from spontaneous activation of auditory cortical areas in the absence of corresponding external stimuli. Serotonergic psychedelics facilitate this through 5-HT2A agonism, which increases spontaneous neural firing in auditory association cortex and disrupts the brain's ability to distinguish internally generated signals from external input. Dissociatives produce auditory hallucinations through NMDA antagonism, which impairs sensory gating mechanisms and can lead to disinhibited firing in temporal lobe auditory regions. Deliriants such as diphenhydramine produce particularly vivid and realistic auditory hallucinations through muscarinic acetylcholine receptor antagonism, which profoundly disrupts the neurotransmitter systems involved in reality testing.
Auditory hallucinations occur across many substance classes but with qualitatively different characters. Psychedelics (LSD, psilocybin, DMT) tend to produce musical and abstract auditory hallucinations, often pleasant and complex.Dissociatives (ketamine, DXM, PCP) can generate immersive sonic environments, particularly during dissociative holes.Deliriants (diphenhydramine, datura) produce the most realistic and often disturbing auditory hallucinations — convincing phantom conversations and environmental sounds that are difficult to distinguish from reality.Cannabis at high doses, particularly edibles, can produce mild auditory hallucinations.Stimulant psychosis from prolonged use of amphetamines or cocaine can generate persecutory auditory hallucinations.
While psychedelic auditory hallucinations are generally benign and often enjoyable, deliriant-induced auditory hallucinations deserve serious caution — they can be indistinguishable from reality and may provoke dangerous behavioral responses. Stimulant-induced auditory hallucinations (especially persecutory voices) are a sign of psychosis and indicate a medical emergency requiring cessation of use and professional help. Individuals with a personal or family history of schizophrenia or psychotic disorders should exercise extreme caution with any substance that produces auditory hallucinations, as these effects may trigger or exacerbate underlying conditions. If hallucinated voices become commanding or frightening, this is a sign to seek immediate support.
Auditory hallucination can manifest at varying intensities depending on the dose of 6-APB and individual sensitivity. The following levels describe the typical progression of this effect.
Vague, ambiguous sounds at the edge of perception — faint whispers, phantom notification sounds, or barely audible music that one cannot be sure is real.
Identifiable sounds with no source — distinct musical snippets, recognizable words or phrases, phantom environmental sounds like a ringing phone.
Clear and detailed auditory hallucinations — full melodies, conversational fragments, or rich environmental soundscapes; one can usually still distinguish them from reality.
Complex, vivid auditory experiences — entire songs with lyrics, coherent conversations, or immersive sonic environments that are difficult to distinguish from real sounds.
Complete auditory hallucination dominance — the hallucinated soundscape is indistinguishable from reality; real and imagined sounds merge into a single perceptual stream.
6-APB is a serotonin–norepinephrine–dopamine reuptake inhibitor (SNDRI) with Ki values of 117, 150, and 2698 nM for the norepinephrine transporter (NET), dopamine transporter (DAT), and serotonin transporter (SERT), respectively. 6-APB also possesses additional activity as a releasing agent of these monoamine neurotransmitters.
6-APB is a potent full agonist of the serotonin 5-HT2B receptor (Ki = 3.7 nM) Moreover, unlike MDMA, 6-APB shows 100-fold selectivity for the 5-HT2B receptor over the 5-HT2A and 5-HT2C receptors.
Aside from the 5-HT2B receptor, 6-APB has also been found to bind with high affinity to the α2C-adrenergic receptor subtype (Ki = 45 nM), although the clinical significance of this action is unknown.
The monoamine neurotransmitters known as serotonin, dopamine and noradrenaline are the global neurotransmitters that modulate the brain's ability to feel pleasure, motivation, reward, planning, attention, and focus. When their reuptake is inhibited or their release is promoted, these neurotransmitters accumulate in the synaptic cleft (gaps between neurons) to non-ordinary levels, which makes them able to be reused. The result is neuronal activation at a multitude of brain regions which has the net result of producing a combination of stimulating, relaxing, disinhibiting and euphoric effects.
Exposing compounds to the reagents gives a colour change which is indicative of the compound under test.
Due to only having a short history of human use, the toxicity and harm potential is not exactly known. Due to its similarity to MDMA, it is likely that the administration of repeated or high dosages of 6-APB may be both neurotoxic and cardiotoxic in some form.exact toxic dosage is unknown. It is strongly recommended that one use harm reduction practices when using this substance.
Short-term physical health risks of 6-APB consumption include dehydration, insomnia, and hyperthermia (overheating). Continuous activity without sufficient rest or rehydration may cause body temperature to rise to dangerous levels, and loss of fluid via excessive sweating puts the body at further risk as the stimulating and euphoric properties of the substance may render the user oblivious to their energy expenditure for quite some time. Diuretics such as alcohol may exacerbate these risks further.
Although it has not been formally studied, small changes in ambient temperature may cause large changes in 6-APB-induced serotonergic neurotoxicity as is the case with MDMA.
The neurotoxicity of 6-APB is subject to ongoing debate. It was specifically designed to be less neurotoxic than MDA or MDMA by circumventing the production of certain metabolic byproducts thought to underlie their toxicity (specifically alpha-methyl-dopamine). Although it is likely to be physically safe to try in a responsible context, it is completely possible that the administration of repeated or high dosages of 6-APB could result in neurotoxicity in some form, presenting as deficits in cognitive, affective and psychomotor function.
As with MDMA, the long-term, heavy usage of 6-APB (i.e. regular daily or weekly usage) is likely cardiotoxic and may lead to valvulopathy (heart valve issues) via its significant affinity for the 5-HT2B receptor. (List 4) substance. It may be used for research and restricted therapeutic purposes. (§ 1, d), 1. of Nařízení vlády č. 463/2013 Sb.)
France: 6-APB is classified as a narcotic since May 9, 2018, alongside other substances derived from benzofuran.
Germany: 6-APB is controlled under Anlage II BtMG (Narcotics Act, Schedule II) as of July 17, 2013. It is illegal to manufacture, possess, import, export, buy, sell, procure or dispense it without a license.
Italy: 6-APB is illegal in Italy.
Japan: 6-APB is a controlled substance in Japan effective December 17th, 2012.
Luxembourg:** 6-APB is not cited in the list of prohibited substances. Therefore, it is still a legal substance.
The Netherlands:** 6-APB is a controlled substance as of July 1, 2025.
Sweden: 6-APB is prohibited in Sweden as a "health hazard" as of 2009.
Switzerland: 6-APB is a controlled substance specifically named under Verzeichnis E.
Turkey:** 6-APB is a classed as drug and is illegal to possess, produce, supply, or import.
United Kingdom: On June 10, 2013, 6-APB and some analogues were classified as Temporary Class Drugs in the U.K. following an ACMD recommendation. On March 5, 2014, the U.K. Home Office announced that 6-APB would be made a class B drug on 10 June 2014 alongside every other benzofuran entactogen and many structurally related drugs.
United States: 6-APB is unscheduled in the United States, but not currently approved by the Food and Drug Administration for human consumption.
Responsible use
Research chemicals
Benzofuran
Entactogen
MDA
6-APB (Wikipedia)
6-APB (Erowid Vault)
6-APB (Isomer Design)
6-APB (Drugs-Forum)
MDMA Wiki
Discussion
The Big & Dandy 6-APB Thread (Bluelight)
Greene, S. L. (2013). Benzofurans and benzodifurans. In Novel Psychoactive Substances (pp. 383-392). https://doi.org/10.1016/B978-0-12-415816-0.00016-X
6-APB can be administered via oral. The route of administration can influence both the onset and intensity of auditory hallucination.
The intensity of auditory hallucination depends heavily on the dose of 6-APB. Effects like auditory hallucination are typically reported at common to strong doses. Below is the full dosage chart for 6-APB.
Warning
Realistic auditory hallucinations, especially from deliriants or stimulant psychosis, can be indistinguishable from reality and may prompt dangerous behavior. Hearing commanding or persecutory voices is a sign of acute psychosis requiring immediate medical attention. Individuals with a history of psychotic disorders should avoid substances that produce this effect.
Yes. Auditory hallucination is a documented auditory effect of 6-APB. Auditory hallucination is the perception of sounds that have no external source — hearing music, voices, environmental noises, or abstract sonic phenomena that exist entirely within the mind. These range from faint, ambiguous whispers at the edge of perception to fully formed, complex musical compositions or conversational speech that can feel completely real and externally sourced.
Effects like auditory hallucination are typically reported at common doses and above. A common oral dose of 6-APB is 60–90 mg.
Other substances documented to produce auditory hallucination include Diphenhydramine, Datura, Dextromethorphan, Methamphetamine, Ibogaine, and 35 more.